Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19218144 | 0.91 | CXCR2 (0.63) | CXCR2 | |
| SCHEMBL19214391 | 0.89 | CXCR2 (0.62) | CXCR2 | |
| SCHEMBL19214396 | 0.85 | CXCR2 (0.56) | CXCR2 | |
| SCHEMBL1562925 | 0.85 | CXCR2 (1.00) | CXCR2 | |
| Hydrochloric Acid SCHEMBL4355911 | 0.84 | CXCR2 (0.98) | CXCR2 | |
| SCHEMBL27003035 | 0.83 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL4162988 | 0.80 | CXCR2 (0.84) | CXCR2 | |
| SCHEMBL19678017 | 0.78 | CXCR2 (0.74) | CXCR2 | |
| SCHEMBL6563380 | 0.78 | CXCR2 (0.80) | CXCR2 | |
| Elubrixin SCHEMBL1562280 | 0.77 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | claimed |
| EP-3174851-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | claimed |
| CN-107027306-B | 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3174851-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016178-A1 | USE OF CXCR2 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY (CIPN) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885 |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885 |
| US-20170224679-A1 | Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) | CXCR2, CXCR3, CCR2 | CXCR2 1/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885 |
| US-20190010135-A1 | Novel Compounds | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.